Literature DB >> 21212274

TAp73 induction by nitric oxide: regulation by checkpoint kinase 1 (CHK1) and protection against apoptosis.

Ali Tebbi1, Olivier Guittet2, Marie-Hélène Cottet2, Marie-Françoise Vesin2, Michel Lepoivre3.   

Abstract

Nitric oxide (NO) is a potent activator of the p53 tumor suppressor protein, thereby inducing cell cycle arrest and apoptosis. However, little is known about the regulation of the two other p53-family members, p63 and p73, by nitrogen oxides. We report here an up-regulation of p73 by NO in p53-null K-562 leukemia cells. Chemical NO prodrugs or macrophage iNOS activity induced an accumulation of the TAp73α isoform in these cells, whereas macrophages from iNOS(-/-) mice did not. NO also up-regulated TAp73 mRNA expression, suggesting a transcriptional regulation. The checkpoint kinases Chk1 and Chk2 can regulate TAp73 induction after DNA damage. We show that these kinases were rapidly phosphorylated upon NO treatment. Genetic silencing or pharmacological inhibition of Chk1 impaired NO-mediated accumulation of TAp73α. Because NO is known to block DNA synthesis through ribonucleotide reductase inhibition, the up-regulation of TAp73α might be caused by DNA damage induced by an arrest of DNA replication forks. In support of this hypothesis, DNA replication inhibitors such as hydroxyurea and aphidicolin similarly enhanced TAp73α expression and Chk1 phosphorylation. Moreover, inhibition of Chk1 also prevented TAp73α accumulation in response to replication inhibitors. The knockdown of TAp73 with siRNA sensitized K-562 cells to apoptosis induced by a nitrosative (NO) or oxidative (H(2)O(2)) injury. Therefore, TAp73α has an unusual cytoprotective role in K-562 cells, contrasting with its pro-apoptotic functions in many other cell models. In conclusion, NO up-regulates several p53 family members displaying pro- and anti-apoptotic effects, suggesting a complex network of interactions and cross-regulations between NO production and p53-related proteins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212274      PMCID: PMC3048674          DOI: 10.1074/jbc.M110.184879

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

Review 1.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

2.  Upregulation of the p53R2 ribonucleotide reductase subunit by nitric oxide.

Authors:  Olivier Guittet; Ali Tebbi; Marie-Hélène Cottet; Françoise Vésin; Michel Lepoivre
Journal:  Nitric Oxide       Date:  2008-04-24       Impact factor: 4.427

Review 3.  p53-family proteins and their regulators: hubs and spokes in tumor suppression.

Authors:  L Collavin; A Lunardi; G Del Sal
Journal:  Cell Death Differ       Date:  2010-04-09       Impact factor: 15.828

4.  Deletion of the COOH-terminal region of p73alpha enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells.

Authors:  T Ozaki; M Naka; N Takada; M Tada; S Sakiyama; A Nakagawara
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

5.  p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes.

Authors:  Konstantinos Lefkimmiatis; Mariano Francesco Caratozzolo; Paola Merlo; Anna Maria D'Erchia; Beatriz Navarro; Massimo Levrero; Elisabetta Sbisa'; Apollonia Tullo
Journal:  Cancer Res       Date:  2009-10-27       Impact factor: 12.701

Review 6.  The chemical biology of nitric oxide: implications in cellular signaling.

Authors:  Douglas D Thomas; Lisa A Ridnour; Jeffrey S Isenberg; Wilmarie Flores-Santana; Christopher H Switzer; Sonia Donzelli; Perwez Hussain; Cecilia Vecoli; Nazareno Paolocci; Stefan Ambs; Carol A Colton; Curtis C Harris; David D Roberts; David A Wink
Journal:  Free Radic Biol Med       Date:  2008-04-04       Impact factor: 7.376

7.  Inhibition of S-phase progression triggered by UVA-induced ROS does not require a functional DNA damage checkpoint response in mammalian cells.

Authors:  Pierre-Marie Girard; Mariaelena Pozzebon; Fabien Delacôte; Thierry Douki; Violetta Smirnova; Evelyne Sage
Journal:  DNA Repair (Amst)       Date:  2008-07-07

8.  Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function.

Authors:  Carla E Cano; Julien Gommeaux; Sylvia Pietri; Marcel Culcasi; Stéphane Garcia; Mylène Seux; Sarah Barelier; Sophie Vasseur; Rose P Spoto; Marie-Josèphe Pébusque; Nelson J Dusetti; Juan L Iovanna; Alice Carrier
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

9.  Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints.

Authors:  Yungan Tao; Céline Leteur; Ceyao Yang; Ping Zhang; Maria Castedo; Alain Pierré; Roy M Golsteyn; Jean Bourhis; Guido Kroemer; Eric Deutsch
Journal:  Cell Cycle       Date:  2009-04-16       Impact factor: 4.534

10.  TAp73 knockout shows genomic instability with infertility and tumor suppressor functions.

Authors:  Richard Tomasini; Katsuya Tsuchihara; Margareta Wilhelm; Masashi Fujitani; Alessandro Rufini; Carol C Cheung; Fatima Khan; Annick Itie-Youten; Andrew Wakeham; Ming-Sound Tsao; Juan L Iovanna; Jeremy Squire; Igor Jurisica; David Kaplan; Gerry Melino; Andrea Jurisicova; Tak W Mak
Journal:  Genes Dev       Date:  2008-09-19       Impact factor: 11.361

View more
  8 in total

1.  Caspase-dependent Proteolysis of Human Ribonucleotide Reductase Small Subunits R2 and p53R2 during Apoptosis.

Authors:  Ali Tebbi; Olivier Guittet; Karine Tuphile; Aimeric Cabrié; Michel Lepoivre
Journal:  J Biol Chem       Date:  2015-04-15       Impact factor: 5.157

2.  Human Periosteal Derived Stem Cell Potential: The Impact of age.

Authors:  Concetta Ferretti; Guendalina Lucarini; Chiara Andreoni; Eleonora Salvolini; Novella Bianchi; Giovanni Vozzi; Antonio Gigante; Monica Mattioli-Belmonte
Journal:  Stem Cell Rev Rep       Date:  2015-06       Impact factor: 5.739

Review 3.  A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.

Authors:  D Engelmann; C Meier; V Alla; B M Pützer
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

4.  Apoptosis induction by combination of drugs or a conjugated molecule associating non-steroidal anti-inflammatory and nitric oxide donor effects in medullary thyroid cancer models: implication of the tumor suppressor p73.

Authors:  Thierry Ragot; Claire Provost; Aurélie Prignon; Régis Cohen; Michel Lepoivre; Sylvie Lausson
Journal:  Thyroid Res       Date:  2015-08-14

5.  TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity.

Authors:  Dongshi Chen; Lihua Ming; Fangdong Zou; Ye Peng; Bennett Van Houten; Jian Yu; Lin Zhang
Journal:  Oncotarget       Date:  2014-09-30

Review 6.  The p53 family member p73 in the regulation of cell stress response.

Authors:  Svetlana Zvereva; Aleksandra Dalina; Igor Blatov; Julian M Rozenberg; Ilya Zubarev; Daniil Luppov; Alexander Bessmertnyi; Alexander Romanishin; Lamak Alsoulaiman; Vadim Kumeiko; Alexander Kagansky; Gerry Melino; Carlo Ganini; Nikolai A Barlev
Journal:  Biol Direct       Date:  2021-11-08       Impact factor: 4.540

7.  Deficiency of multidrug resistance 2 contributes to cell transformation through oxidative stress.

Authors:  Ali Tebbi; Florence Levillayer; Grégory Jouvion; Laurence Fiette; Guillaume Soubigou; Hugo Varet; Nesrine Boudjadja; Stefano Cairo; Kosuke Hashimoto; Ana Maria Suzuki; Piero Carninci; Annamaria Carissimo; Diego di Bernardo; Yu Wei
Journal:  Carcinogenesis       Date:  2015-11-05       Impact factor: 4.944

Review 8.  Dual Role of p73 in Cancer Microenvironment and DNA Damage Response.

Authors:  Julian M Rozenberg; Svetlana Zvereva; Alexandra Dalina; Igor Blatov; Ilya Zubarev; Daniil Luppov; Alexander Bessmertnyi; Alexander Romanishin; Lamak Alsoulaiman; Vadim Kumeiko; Alexander Kagansky; Gerry Melino; Nikolai A Barlev
Journal:  Cells       Date:  2021-12-13       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.